Compare Abbott Laboratories (ABT) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs iShares MSCI South Korea ETF — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while iShares MSCI South Korea ETF trades at $179.62. The key difference: Abbott Laboratories pays a 2.63% dividend while iShares MSCI South Korea ETF pays none, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | EWY | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $219.20 |
52-Week Low | $82.57 | $70.65 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
The iShares MSCI South Korea ETF (EWY) trades at $189.85, up 5.33% over 24 hours, amid volatile South Korean equity markets. Technical indicators show a bearish trend with key support at $185 and resistance at $192. Recent news highlights strong AI-driven semiconductor demand boosting South Korean stocks, but weak EV battery demand and market volatility pose headwinds.
EWY's outlook hinges on AI memory demand and Samsung's performance, with potential gains from SK Hynix's U.S. listing. Risks include semiconductor cycle volatility and foreign investor selling. The ETF remains a high-beta play on South Korea's tech sector, requiring careful risk management amid elevated market swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
